Plain-English fact sheet
Ipamorelin
Also known as ipamorelin acetate
Ipamorelin is not FDA approved, and evidence for common wellness or body-composition claims is limited.
Quick answer
Ipamorelin is an experimental peptide that can stimulate growth-hormone release. It is not an FDA-approved medicine, and FDA has described important evidence gaps and potential safety concerns.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Ipamorelin?
Ipamorelin is a synthetic growth hormone secretagogue that acts at the ghrelin receptor.
It has been investigated in human research, including studies of gastrointestinal motility, but that does not establish common online claims.
Why are people interested in it?
It is promoted for muscle, recovery, sleep, fat loss, and anti-aging, often in combination with CJC-1295.
Combination marketing makes it harder to know which ingredient caused an effect or adverse event.
Current regulatory status
Ipamorelin is not FDA approved. FDA has described potential immunogenicity and impurity concerns and insufficient safety information for certain routes.
What is it approved for?
No FDA-approved use. This matters because clinical-trial participation and products marketed online are not the same as an approved medicine.
What is it being studied for?
Investigational areas
- Growth-hormone and gastrointestinal pathway effects
Evidence snapshot
Human studies exist, but they do not provide strong evidence for the broad performance, recovery, or anti-aging outcomes promoted to consumers.
Potential benefits being researched
- Studies confirm pharmacologic effects on hormone signaling.
- Evidence does not yet establish a favorable benefit-risk profile for popular consumer uses.
Potential does not mean proven. Study design, population, endpoint, and regulatory review matter.
Known or possible risks
- FDA describes potential immune reactions and complexities related to impurities and peptide characterization.
- FDA notes serious adverse events, including deaths, in a study using intravenous ipamorelin for gastric motility; that context does not establish cause for every event but is a serious signal.
- Safety information for other routes and long-term use is insufficient.
What we still do not know
- Long-term safety and uncommon adverse effects
- Meaningful benefits for body composition, recovery, sleep, or aging
- Safety of combinations promoted online
- Product identity, purity, and consistency outside approved manufacturing
Plain-English takeaway
Ipamorelin affects a real biological pathway, but it is unapproved and lacks strong evidence for the outcomes commonly used to market it.
Research and reference links
Use these primary and reputable sources to verify status and read beyond this summary. Trial registries may list studies without proving a benefit.
- 1FDA: bulk substances that may present significant safety risks
FDA summaries of safety concerns and evidence gaps for selected bulk substances used in compounding.
- 2ClinicalTrials.gov studies: ipamorelin
Current and completed registered clinical studies.
- 3PubMed research: ipamorelin
Peer-reviewed literature indexed by the National Library of Medicine.